Use of Tyrosine Kinase Inhibitors to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Position Statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
[en] Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a standard of care for patients with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL). The introduction of tyrosine kinase inhibitors (TKIs) to first-line therapy has improved overall outcomes; however, a significant proportion of patients still relapse after alloHSCT. Posttransplant TKI maintenance was demonstrated to reduce the risk of relapse in a large retrospective study and, therefore, should be considered a valuable option. This consensus paper, written on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, presents an overview of clinical studies on the use of TKIs after alloHSCT and proposes practical recommendations regarding the choice of TKI, treatment timing, and dosage. It is hoped that these recommendations will become the state of art in this field and, more importantly, lead to a reduction of Ph-positive ALL relapse after alloHSCT.
Use of Tyrosine Kinase Inhibitors to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Position Statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Bloomfield CD,Rowley JD,Goldman AI,et al. Chromosomal abnormalities and their clinical significance in acute lymphoblastic leukemia. Third International Workshop on Chromosomes in Leukemia. Cancer Res. 1983;43:868-873.
Burmeister T,Schwartz S,Bartram CR,et al. Patients’ age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. Blood. 2008;112:918-919.
Moorman AV,Harrison CJ,Buck GA,et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109:3189-3197.
Dombret H,Gabert J,Boiron JM,et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia—results of the prospective multicenter LALA-94 trial. Blood. 2002;100:2357-2366.
Wrzesien-Kus A,Robak T,Pluta A,et al. Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR-ABL-positive acute lymphoblastic leukemia—retrospective analysis of Polish Adult Leukemia Group (PALG). Ann Hematol. 2006;85:366-373.
Thomas DA,Faderl S,Cortes J,et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103:4396-4407.
de Labarthe A,Rousselot P,Huguet-Rigal F,et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood. 2007;109: 1408-1413.
Wassmann B,Pfeifer H,Goekbuget N,et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph1 ALL). Blood. 2006;108:1469-1477.
Yanada M,Sugiura I,Takeuchi J,et al. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinibcombined chemotherapy. Br J Haematol. 2008;143:503-510.
Ribera JM,Oriol A,Gonzalez M,et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica. 2010;95:87-95.
Mizuta S,Matsuo K,Yagasaki F,et al. Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL positive acute lymphoblastic leukemia. Leukemia. 2011;25:41-47.
Chalandon Y,Thomas X,Hayette S,et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125: 3711-3719.
Bachanova V,Marks DI,Zhang MJ,et al. Ph1 ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia. 2014;28:658-665.
Brissot E,Labopin M,Beckers MM,et al. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica. 2015;100: 392-399.
Shimoni A,Kroger N,Zander AR,et al. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia. 2003;17:290-297.
Radich J,Gehly G,Lee A,et al. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood. 1997;89:2602-2609.
Wassmann B,Pfeifer H,Stadler M,et al. Early molecular response to posttransplantation imatinib determines outcome in MRD1 Philadelphia-positive acute lymphoblastic leukemia (Ph1 ALL). Blood. 2005;106:458-463.
Carpenter PA,Snyder DS,Flowers ME,et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for highrisk Philadelphia chromosome-positive leukemia. Blood. 2007;109: 2791-2793.
Chen H,Liu KY,Xu LP,et al. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. J Hematol Oncol. 2012;5:29.
Pfeifer H,Wassmann B,Bethge W,et al. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia. 2013;27:1254-1262.
Shimoni A,Volchek Y,Koren-Michowitz M,et al. Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015; 121:863-871.
Nishiwaki S,Miyamura K,Kato C,et al. Impact of post transplant imatinib administration on Philadelphia chromosome-positive acute lymphoblastic leukaemia. Anticancer Res. 2010;30:2415-2418.
Kebriaei P,Saliba R,Rondon G,et al. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant. 2012;18:584-592.
Czyz A,Lewandowski K,Kroll R,Komarnicki M. Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion. Med Oncol. 2008;27:1123-1126.
Caocci G,Vacca A,Ledda A,et al. Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2012;18:652-654.
Fava C,Rege-Cambrin G,Busca A,et al. Second-generation tyrosine kinase inhibitors can induce complete molecular response in Phpositive acute lymphoblastic leukemia after allogeneic stem cell transplant. Clin Lymphoma Myeloma Leuk. 2013;13(suppl 2):S272-S275.
Watanabe A,Chansu S,Ogawa A,et al. Prophylactic post-transplant dasatinib administration in a pediatric patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. Pediatr Int. 2013;55:e56-e58.
Teng CL,Yu JT,Chen HC,Hwang WL. Maintenance therapy with dasatinib after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Hematol. 2013;92:1137-1139.
Soverini S,De Benedittis C,Papayannidis C,et al. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations,but not in the frequency of mutation involvement. Cancer. 2014;120:1002-1009.
Egan DN,Beppu L,Radich JP. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation. Biol Blood Marrow Transplant. 2015;21:184-189.
Soverini S,Hochhaus A,Nicolini FE,et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118:1208-1215.
Kastner R,Zopf A,Preuner S,et al. Rapid identification of compound mutations in patients with Philadelphia-positive leukemias by long-range next generation sequencing. Eur J Cancer. 2014;50:793-800.
Takayama N,Sato N,O’Brien SG,et al. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol. 2002;119: 106-108.
Leis JF,Stepan DE,Curtin PT,et al. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma. 2004;45:695-698.
Pfeifer H,Wassmann B,Hofmann WK,et al. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res. 2003;9:4674-4681.
Porkka K,Koskenvesa P,Lundan T,et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008; 112:1005-1012.
Gutierrez-Aguirre H,Garcia-Rodriguez F,Cantu-Rodriguez O,et al. Effectiveness of dasatinib in relapsed CNS,Ph1 ALL that is refractory to radiochemotherapy plus imatinib: a case report. Clin Adv Hematol Oncol. 2011;9:875-878.
Nishimoto M,Nakamae H,Koh KR,et al. Dasatinib maintenance therapy after allogeneic hematopoietic stem cell transplantation for an isolated central nervous system blast crisis in chronic myelogenous leukemia. Acta Haematol. 2013;130:111-114.
Kondo T,Tasaka T,Matsumoto K,et al. Philadelphia chromosome-positive acute lymphoblastic leukemia with extramedullary and meningeal relapse after allogeneic hematopoietic stem cell transplantation that was successfully treated with dasatinib. Springerplus. 2014;3:177.
Pfeifer H,Wassmann B,Pavlova A,et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph1 ALL). Blood. 2007;110:727-734.
Savani BN,Montero A,Kurlander R,et al. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant. 2005;36:1009-1015.
Cortes JE,Kantarjian H,Shah NP,et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012; 367:2075-2088.
Cortes JE,Kim DW,Pinilla-Ibarz J,et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783-1796.
Hirschbuehl K,Rank A,Pfeiffer T,et al. Ponatinib given for advanced leukemia relapse after allo-SCT. Bone Marrow Transplant. 2015;50:599-600.
Topp MS,Gokbuget N,Stein AS,et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre,single-arm,phase 2 study. Lancet Oncol. 2015;16:57-66.
Iacobucci I,Lonetti A,Venturi C,et al. Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response. Leuk Res. 2014;38:581-585.
Banovic T,MacDonald KP,Morris ES,et al. TGF-beta in allogeneic stem cell transplantation: friend or foe? Blood. 2005;106:2206-2214.
Svegliati S,Olivieri A,Campelli N,et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versushost disease. Blood. 2007;110:237-241.
Magro L,Mohty M,Catteau B,et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood. 2009;114:719-722.
Olivieri A,Locatelli F,Zecca M,et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood. 2009; 114:709-718.
Nakasone H,Kanda Y,Takasaki H,et al. Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia. Leukemia. 2010;24:1236-1239.
Wetzler M,Watson D,Stock W,et al. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica. 2014;99:111-115.
Giebel S,Labopin M,Gorin NC,et al. Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: a report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Eur J Cancer. 2014;50:411-417.
